| Kenneth Mitchum Maynard, DO | |
|
1045 Wyatt Way, Lizton, IN 46149-9583 | |
| (317) 994-6600 | |
| (317) 994-6605 |
| Full Name | Kenneth Mitchum Maynard |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 40 Years |
| Location | 1045 Wyatt Way, Lizton, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730103730 | NPI | - | NPPES |
| 200932990 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02000836A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hendricks Regional Health | Danville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hendricks County Hospital | 4880505528 | 274 |
News Archive
The patient-centered medical home (PCMH) model is an emerging team-based approach for primary health care. PCMH is aimed at improving timely access to care, providing continuity of care by a health care team and lowering health care costs. PCMH aims to alleviate future health problems through tailored health care that focuses on patient wellness and prevention.
Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS), the Center for Integrative Biomedical Sciences, and the Center for Genomic Medicine at the Geisel School of Medicine are studying the unknown causes of premature birth, as part of a $10 million March of Dimes grant awarded to a research collaborative of seven U.S. universities and medical centers.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.
Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 2 days ago
| Entity Name | Hendricks County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063411551 PECOS PAC ID: 4880505528 Enrollment ID: O20040811000309 |
News Archive
The patient-centered medical home (PCMH) model is an emerging team-based approach for primary health care. PCMH is aimed at improving timely access to care, providing continuity of care by a health care team and lowering health care costs. PCMH aims to alleviate future health problems through tailored health care that focuses on patient wellness and prevention.
Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS), the Center for Integrative Biomedical Sciences, and the Center for Genomic Medicine at the Geisel School of Medicine are studying the unknown causes of premature birth, as part of a $10 million March of Dimes grant awarded to a research collaborative of seven U.S. universities and medical centers.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.
Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 2 days ago
| Entity Name | Medexpress Urgent Care Pc Indiana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609114578 PECOS PAC ID: 8325286834 Enrollment ID: O20130522000565 |
News Archive
The patient-centered medical home (PCMH) model is an emerging team-based approach for primary health care. PCMH is aimed at improving timely access to care, providing continuity of care by a health care team and lowering health care costs. PCMH aims to alleviate future health problems through tailored health care that focuses on patient wellness and prevention.
Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS), the Center for Integrative Biomedical Sciences, and the Center for Genomic Medicine at the Geisel School of Medicine are studying the unknown causes of premature birth, as part of a $10 million March of Dimes grant awarded to a research collaborative of seven U.S. universities and medical centers.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.
Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kenneth Mitchum Maynard, DO 1100 Southfield Dr, Suite 1370, Plainfield, IN 46168-4498 Ph: (317) 837-5571 | Kenneth Mitchum Maynard, DO 1045 Wyatt Way, Lizton, IN 46149-9583 Ph: (317) 994-6600 |
News Archive
The patient-centered medical home (PCMH) model is an emerging team-based approach for primary health care. PCMH is aimed at improving timely access to care, providing continuity of care by a health care team and lowering health care costs. PCMH aims to alleviate future health problems through tailored health care that focuses on patient wellness and prevention.
Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS), the Center for Integrative Biomedical Sciences, and the Center for Genomic Medicine at the Geisel School of Medicine are studying the unknown causes of premature birth, as part of a $10 million March of Dimes grant awarded to a research collaborative of seven U.S. universities and medical centers.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.
Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 2 days ago
Jennifer L Behrens, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 W Main St, Lizton, IN 46149 Phone: 317-520-2926 Fax: 585-312-6697 | |
David M Stopperich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1045 Wyatt Way, Lizton, IN 46149 Phone: 317-994-6600 Fax: 317-994-6605 |